Johnson & Johnson (JNJ)

Acerca de Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

Al 3 de noviembre de 2026, la acción de Johnson & Johnson (JNJ) retrocedió ligeramente a $269.43, una baja de 0.42% (-$1.13) frente al cierre anterior. En la sesión, las acciones han operado entre $267.74 y $270.56. Eso ubica a JNJ en el tercio superior de su rango de 52 semanas, de $185.12 a $282.02. Johnson & Johnson opera en el sector de pharmaceutical preparations y tiene una capitalización de mercado de aproximadamente $657.68 mil millones, con cerca de 458.1 mil acciones negociadas.

Últimas noticias de JNJ

• What Could Derail Bristol Myers Squibb Stock?trefis.com· 3 nov, 9:12 a.m. ET
• Is Intuitive Surgical Stock Worth More Than Its Competitors?trefis.com· 3 nov, 8:39 a.m. ET
• Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?Yahoo Finance· 3 nov, 8:00 a.m. ET
• Why Did Boston Scientific Stock Jump?trefis.com· 3 nov, 7:41 a.m. ET
• Kimberly-Clark Acquires Kenvue. Here’s What Investors Need to Know Ahead of Its Nov. 5 Earnings Report.fool.com· 3 nov, 1:20 a.m. ET
• 5 Top Stocks That Belong in a Retirement Portfoliotikr.com· 2 nov, 3:39 p.m. ET
• Betting On Drug Sales: Is Viatris Or Lilly The Better Way In?trefis.com· 2 nov, 3:21 p.m. ET
• Johnson & Johnson (JNJ) As Impella Data Fuels The Story, Is The Stock Fully Valued?Yahoo Finance· 2 nov, 2:09 p.m. ET

Fuente: Yahoo Finance RSS · Actualizado el 3 de noviembre de 2026

¿Quieres titulares, alertas e investigación con IA de JNJ en un solo lugar? Crea una cuenta gratis →

• $ABCL $MRNA $REGN $SLS $JNJ Now everyone is finding themselves chasing… All those sellers are now buying it up. Earnings coming up in a few days …November 9th Follow by 2 huge biotech conferences that they will be presenting at. November 9: Q3 earnings and pipeline update. Nov…

  @Stocktradesmoon· 3 nov, 9:41 a.m. ET· Alcista

• $SLS $RVMD $MRNA $JNJ Sellas GPS Regal Pivotal Registrational Phase 3 study Paradigm Shifting success = $120.00+ before BO because it’s the master key to 20+ other WT1 cancers. ✌️🙏❤️‍🩹

  @SellasgpsCurativeBAT11· 3 nov, 7:51 a.m. ET· Alcista

• JPMorgan🏁 $TRXB and said--We are initiating coverage of TRexBio (TRXB) with an OW rating and a Dec- 2027 PT of $20. [ $JNJ $LLY [ABBV SNY - REGN PFE CRVS QTTB MANE NKTR CLDX Dren Bio, ALYS Pharma, Legacy Healthcare, Reistone, Suzhou, EVMN KYMR BCRX ACRX]] JPMorgan went on to …

  @Quantumup· 3 nov, 7:18 a.m. ET

• $SLS $MRNA $RVMD $JNJ Sellas SSR in effect going in to Major Catalysts in Sellas Corporate history. 20,000 HTB shares available to short. 👇 ✌️🙏❤️‍🩹

  @SellasgpsCurativeBAT11· 3 nov, 7:17 a.m. ET· Alcista

• Off-exchange trading in $JNJ was above normal at about 1.3x. The full read shows the session-by-session dark pool share and which institutions are adding or cutting. The full dark-pool read, with the options side: https://globaltradersacademy.com/articles/dark-pool-activity-wh…

  @GlobalTradersAcademy· 3 nov, 2:06 a.m. ET

Fuente: Stocktwits. Las publicaciones de usuarios son opiniones, no hechos verificados. Ver lo que es tendencia →